Clinical Trial Update: Subcutaneously CM310/Placebo in Patients With Moderate-to-Severe Atopic Dermatitis (AD) [Phase 2]

View source ↗

Summary

Phase 2 trial update of subcutaneously administered CM310 vs placebo in moderate-to-severe atopic dermatitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• CM310

Snippet

Sponsor: Keymed Biosciences Co.Ltd | Conditions: Moderate-to-severe Atopic Dermatitis | Phase 2 | Status: COMPLETED